Kiora Pharmaceuticals
KPRX
Kiora Pharmaceuticals (KPRX) earnings history
Most recent quarter
- Fiscal period
- Q3 2025
- Period end
- Sep 30, 2025
- EPS actual
- $0.01
- EPS estimate
- −$0.74
- EPS surprise
- +101.36%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $750,000.00
- Reported
- Nov 7, 2025
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q3 2025 | Nov 7, 2025 | −$0.74 | $0.01 | +101.36% | $0.00 | SEC |
| Q2 2025 | Aug 8, 2025 | −$0.61 | −$0.54 | +10.74% | $750,000.00 | SEC |
| Q1 2025 | May 9, 2025 | −$0.67 | −$0.52 | +22.39% | $0.00 | SEC |
| Q4 2024 | Mar 25, 2025 | −$0.55 | −$1.21 | −120.00% | $0.00 | SEC |
| Q3 2024 | Nov 8, 2024 | −$0.76 | −$0.81 | −6.12% | $0.00 | SEC |
| Q2 2024 | Aug 9, 2024 | −$0.86 | −$0.53 | +38.13% | $20,000.00 | SEC |
| Q1 2024 | May 10, 2024 | $2.48 | $3.42 | +38.18% | $16.0M | SEC |
| Q4 2023 | Mar 25, 2024 | −$3.51 | −$2.61 | +25.64% | $0.00 | SEC |
| Q3 2023 | Nov 9, 2023 | −$4.68 | −$8.01 | −71.15% | $0.00 | SEC |
| Q2 2023 | Aug 8, 2023 | −$9.59 | −$7.11 | +25.82% | $0.00 | SEC |
| Q3 2022 | Nov 9, 2022 | −$34.52 | −$54.27 | −57.24% | $0.00 | — |
| Q2 2022 | Aug 12, 2022 | −$81.00 | −$64.80 | +20.00% | $0.00 | — |
| Q1 2022 | Jul 8, 2022 | −$82.80 | −$97.20 | −17.39% | $0.00 | — |
| Q4 2021 | Apr 15, 2022 | −$95.40 | −$237.60 | −149.06% | $0.00 | — |
| Q3 2021 | Nov 15, 2021 | −$121.20 | −$104.40 | +13.86% | $0.00 | — |
| Q2 2021 | Aug 12, 2021 | −$150.00 | −$126.00 | +16.00% | $0.00 | — |
| Q1 2021 | May 12, 2021 | −$138.60 | −$133.20 | +3.90% | $0.00 | — |
| Q4 2020 | Mar 25, 2021 | −$158.40 | −$183.60 | −15.91% | $0.00 | — |
| Q3 2020 | Nov 9, 2020 | −$151.20 | −$158.40 | −4.76% | $0.00 | — |
| Q1 2020 | May 6, 2020 | $0.00 | −$154.80 | +0.00% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Kiora Pharmaceuticals (KPRX) last report earnings?
Kiora Pharmaceuticals last reported on Nov 7, 2025, covering fiscal Q3 2025.
Did KPRX beat earnings estimates?
Yes. Kiora Pharmaceuticals reported EPS of $0.01 for Q3 2025 against a −$0.74 estimate — a 101.36% beat.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.